Many investors do not accept historical controls as proof of concept that a drug works.
True, which is why only SOME investors are able to get in on the ground floor.
Unfortunately, while the FDA gets thru its lawyering of a given new drug, many patients are dying, even though the best specialists (oncologists at premier institutions) KNOW that the drug works, based on their sophisticated KB and medical intuitions.
I think it's a very good investment strategy to look to the thought leaders in the trenches, and invest based on their assessments, even if there is no control arm.
the lack of control arms in the trials completed to date is utterly germane to the valuation of the stock
True, which is why you can still buy ADXS in the sixes! What is "utterly germane" to me is the reasonable expectation of success, based on "proof of concept" as it is at this time!
We know that the general approach of identifying specific tumor antigens is creating tremendous excitement in the medical community AND that Advaxis' delivery platform has shown its efficacy. Enough "proof of concept" for me.